2025年欧洲呼吸学会成人支气管扩张症指南:初级保健实施摘要
本文总结了2025年欧洲呼吸学会更新的成人支气管扩张症全球临床实践指南,重点面向初级保健的实施。内容涵盖早期识别、标准化病因与可治疗特征检查、痰微生物学(含非结核分枝杆菌检测)、靶向血液检查、气道廓清、肺康复、吸入治疗及急性加重管理,并明确吸入糖皮质激素作用有限。
要点
- 提高早期识别、减少诊断延迟,标准化检查病因与可治疗特征。
- 重视痰微生物学(含非结核分枝杆菌)及免疫球蛋白、ABPA血清学检查。
- 吸入糖皮质激素在支气管扩张症中作用有限,急性加重管理有别于哮喘和慢阻肺。
核心结论
- 将2025年ERS成人支气管扩张症指南推荐转化为初级保健实施建议,以支持及时诊断、优化长期管理并改善结局。
研究设计与样本
- 本文为2025年欧洲呼吸学会成人支气管扩张症全球临床实践指南的初级保健实施摘要,非原始研究。
主要发现
- 支气管扩张症估计影响约1/200成人,患病率、住院率和死亡率上升,症状负担和医疗费用显著,主要由急性加重驱动。
- 关键优先事项包括提高早期识别、减少诊断延迟、标准化检查以识别病因和可治疗特征,并识别需专科转诊的不良结局相关特征。
关键数值与推荐
- 指南强调痰微生物学检查,包括非结核分枝杆菌检测,以及靶向血液检查如免疫球蛋白和变应性支气管肺曲霉病血清学。
- 初级保健相关核心管理策略包括气道廓清技术、肺康复和基于证据的吸入治疗使用。
临床怎么用
- 初级保健应关注支气管扩张症的早期识别和标准化检查,管理多病共存和急性加重。
- 识别可能受益于长期抗生素治疗(包括铜绿假单胞菌感染者)的患者并进行监测。
局限性
- 本文为指南实施摘要,非原始研究,未报告原始研究样本量、置信区间或P值等数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
NPJ Prim Care Respir Med. 2026 Jun 8;36(1):62. doi: 10.1038/s41533-026-00528-z. ABSTRACT Bronchiectasis is a common chronic respiratory disease with rising prevalence, hospitalisation rates, and mortality. It is estimated to affect approximately 1 in 200 adults, imposing a substantial symptom burden and significant healthcare costs, largely driven by exacerbations. Although diagnosis and long-term management are usually led by respiratory specialists, most patient care interactions occur in primary care, including the management of multimorbidity and acute exacerbations. In December 2025, the European Respiratory Society (ERS) published updated global clinical practice guidelines for adult bronchiectasis. This article summarises the 2025 ERS recommendations with a specific focus on their implementation in primary care practice. Key priorities include improving early recognition and reducing diagnostic delay, undertaking standardised investigations to identify underlying causes and treatable traits, and recognising features associated with poor outcomes that warrant specialist referral. The guidance emphasises the importance of sputum microbiology, including testing for non-tuberculous mycobacteria, and targeted blood investigations such as immunoglobulins and allergic bronchopulmonary aspergillosis serology. Core management strategies relevant to primary care are reviewed, including airway clearance techniques, pulmonary rehabilitation, and evidence-based use of inhaled therapies. The article outlines best practice for the management of acute exacerbations, highlights differences from asthma and COPD care, and clarifies the limited role of inhaled corticosteroids in bronchiectasis. The identification and monitoring of patients who may benefit from long-term antibiotic therapy, including those with Pseudomonas aeruginosa infection, are also discussed. By translating specialist guideline recommendations into a primary care context, this summary aims to support timely diagnosis, optimise ongoing management, and improve outcomes for adults with bronchiectasis. PMID: 42259823 | PMC: PMC13586304 | DOI: 10.1038/s41533-026-00528-z
引用
- 指南共识 · 慢阻肺:The European respiratory society guideline for adult bronchiectasis 2025: summary and implementation guide for primary care
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。